1. Home
  2. PCB vs KALA Comparison

PCB vs KALA Comparison

Compare PCB & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PCB Bancorp

PCB

PCB Bancorp

N/A

Current Price

$21.93

Market Cap

313.0M

Sector

Finance

ML Signal

N/A

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

N/A

Current Price

$0.31

Market Cap

319.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCB
KALA
Founded
2003
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
313.0M
319.6M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
PCB
KALA
Price
$21.93
$0.31
Analyst Decision
Hold
Buy
Analyst Count
2
3
Target Price
$24.50
$31.50
AVG Volume (30 Days)
19.1K
696.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.00%
N/A
EPS Growth
N/A
41.50
EPS
1.94
N/A
Revenue
$2,774,000.00
N/A
Revenue This Year
$13.73
N/A
Revenue Next Year
$9.07
N/A
P/E Ratio
$11.35
N/A
Revenue Growth
4.68
N/A
52 Week Low
$16.02
$0.26
52 Week High
$24.20
$20.58

Technical Indicators

Market Signals
Indicator
PCB
KALA
Relative Strength Index (RSI) 40.79 35.92
Support Level $21.12 N/A
Resistance Level $22.30 $0.72
Average True Range (ATR) 0.70 0.04
MACD -0.13 -0.00
Stochastic Oscillator 32.56 42.26

Price Performance

Historical Comparison
PCB
KALA

About PCB PCB Bancorp

PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: